[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carotid-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carotid-artery-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100608332","phase-3-perioperative-argon-inhalation-to-improve-neurocognitive-recovery-after-carotid-surgery-100608332",false,"NCT07200180","Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery","Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery (PAIRS Trial)","Inclusion Criteria:\n\n* age \\> 18 years\n* elective carotid artery surgery\n* general anesthesia\n* written informed consent\n\nExclusion Criteria:\n\n* The presence of any mental disorder according to the International Classification of Diseases 10th Revision which is confirmed by a psychiatrist.\n* The presence of any neuromuscular disease according to the International Classification of Diseases 10th Revision\n* Heart failure equal 3 or 4 class according to the New York Heart Association Functional Classification\n* Pregnant or breast-feeding women\n* Inability to undergo a preoperative assessment for any reason\n* Previously enrolled in this trial","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Currently, over 400,000 reconstructive surgeries on carotid arteries are performed annually worldwide, including carotid endarterectomy (CEA) and carotid stenting. These interventions have proven effective in preventing ischemic stroke in patients with hemodynamically significant carotid artery stenoses. However, even following a technically successful procedure, the risk of perioperative ischemic brain injury persists. According to meta-analyses, one in five patients exhibits covert (\"silent\") strokes after reconstructive interventions, with their frequency being ten times higher than that of clinically manifest events. Such lesions are associated with cognitive decline and an increased risk of dementia. An additional risk factor is the \"no-reflow\" phenomenon-an impairment of microcirculatory reperfusion that occurs even after the restoration of macrovascular blood flow, thereby limiting the effectiveness of surgical revascularization.\n\nCognitive disorders and postoperative delirium, observed in 15-30% of patients after CEA, adversely affect rehabilitation and long-term prognosis. To date, there are no reliable pharmacological strategies to prevent these complications.\n\nIn this context, inert gases have attracted significant interest as potential neuroprotective agents. Xenon, despite its proven efficacy, is limited by high cost and challenges in industrial production. Argon, in contrast, is accessible, safe, and technologically straightforward to administer. In preclinical models of stroke and ischemia-reperfusion, argon has demonstrated pronounced anti-apoptotic, anti-inflammatory, and antioxidant effects, mediated through the regulation of TLR2\u002F4-, ERK1\u002F2-, Nrf2-, and NF-κB-dependent signaling pathways. Its ability to suppress microglial activation towards the M1 phenotype and inhibit the NLRP3 inflammasome has been noted, which reduces neuroinflammation and decreases the volume of secondary neuronal damage. Short-term argon inhalation in healthy volunteers has shown a favorable safety profile with no adverse effects on cerebral hemodynamics.\n\nThus, it is highly relevant to clinically test the hypothesis that perioperative inhalation of an argon-containing gas mixture can reduce the incidence of ischemic brain injuries and cognitive impairments in patients undergoing CEA.",[26,27],"Carotid Artery Disease","Carotid Artery Stenoses",[29,30,31,32,33,34,35,36,37],"Carotid artery disease","Carotid artery stenosis","Carotid artery surgery","Neurocognitive disorders","postoperative delirium","Stroke","Neuroinflammation","Argon","Organ protection","RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-18","ACTUAL",{"date":44,"type":42},"2025-09-22",{"date":46,"type":20},"2026-11-01",{"name":48,"class":49},"Negovsky Reanimatology Research Institute","OTHER_GOV",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100605762","high-coverage-carotid-stenting-vs-medical-management-alone-to-prevent-embolism-from-symptomatic-non-stenotic-carotid-disease-sync-100605762","NCT07166731","High Coverage CARotid Stenting vs. Medical Management Alone to Prevent EmboliSm From symptomaTic Non-stenotic cARotid Disease (SyNC)","High Coverage CARotid Stenting vs. Medical Management Alone to Prevent EmboliSm From symptomaTic Non-stenotic cARotid Disease (SyNC) - CARESTAR","CARESTAR","Inclusion Criteria:\n\n* Patients diagnosed with acute ischemic stroke or acute retinal artery ischemia within the last two weeks related to symptomatic non-stenotic carotid disease (SyNC) and high-risk carotid plaque features\n\n  * Ipsilateral acute ischemic stroke must be determined by acute ischemic infarct on DWI or CT OR\n  * by neurological symptoms indicating ipsilateral cortical deficits consistent with ischemia in the territory of the internal carotid artery and after exclusion of a significant microangiopathy\n  * Acute retinal artery ischemia must be determined by ophthalmologic examination\n* Patients with no other identifiable cause of stroke, evaluated using standard echocardiographic examinations to exclude cardiogenic or aortogenic sources of embolism\n* Symptomatic non-stenotic carotid disease defined as one or more plaques in the ipsilateral internal carotid artery causing 10-49% luminal narrowing AND\n* Presence of high-risk plaque features which must be determined through visual inspection on CTA or MRI (Ultrasound findings alone are insufficient; features must be confirmed by CTA or MRI to meet the criteria):\n\n  * Identification of at least two of the following characteristics Plaque thickness ≥ 3mm Irregular plaque surface Ulceration \\\u003C50% plaque calcification Lipid-rich necrotic core\n  * and\u002For identification of at least one of the following characteristics Intraplaque haemorrhage\n* Presence of carotid web characterized as shelf-like\u002Flinear, smooth filling defects\n* Plaque assessment including evaluation of the presence of high-risk features by routine imaging (CTA, MRI) confirmed by an independent CoreLab\n* Signed Informed Consent Form\n* Patient ≥ 18 years\n* mRS ≤ 3 at time of randomisation\n* Dual antiplatelet therapy (DAPT) according to standard of care before endovascular treatment\n\nExclusion Criteria:\n\n* Patients with acute complete occlusion of the carotid artery in an emergency setting\n* Incidence of acute infarcts in other vascular (i.e., not ipsilateral carotid) territories\n* Patients in whom the stroke was likely caused by one of the following diseases:\n* Small vessel disease\n\n  * Large vessel atherosclerotic disease ≥ 50%\n  * Cardioembolism\n  * Other known disease e.g. vasculitis\n* Predominantly calcified Plaques (≥50% calcified plaque components on CT-Angio)\n* Patients presenting with intraluminal carotid thrombus (e.g. characterized by 'donut sign' on CTA)\n* Patients with highly tortuous vessels (\\>90°) which may prevent access or safe insertion of the stent\n* Patients with post-CEA re-stenosis or post-CAS re-stenosis\n* Patients with blood coagulation disorders\n* Patients in whom access to the carotid lesion is impossible or associated with an increased risk of procedural complications\n* Patients with lesions in the ostium of the common carotid artery\n* Patients with known hypersensitivity to nickel-titanium\n* Patients who are allergic to heparin\n* Any known conditions that affect life expectancy to less than 12 months\n* Any known conditions associated with an increased risk of endovascular treatment\n* Patients not able to visit the outpatient clinic for annual follow-up",{"count":60,"type":20},536,"OBSERVATIONAL","Goal is to analyse the clinical safety and efficacy of the CARESTO® heal Stent within standard clinical routine for the treatment of patients with symptomatic non-stenotic carotid disease (SyNC) and with high-risk plaque features for stroke recurrence compared to medical treatment alone with respect to the mid- and long-term clinical outcomes.",[26,64,65,66,67,68],"Symptomatic Carotid Artery Stenosis","Carotid Artery Stenting","Carotid Plaque Imaging","Embolic Stroke of Undetermined Source","Carotid Artery Thrombosis",[70,29,71,72,73,74],"SyNC","carotid artery stenting","symptomatic non-stenotic carotid artery disease","carotid artery stenosis","symptomatic carotid artery stenosis","2026-03-03",{"date":77,"type":42},"2026-03-04",{"date":79,"type":42},"2026-03-01",{"date":81,"type":20},"2032-06",{"name":83,"class":84},"Acandis GmbH","INDUSTRY",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":61,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":85},"100274311","svs-vqi-transcarotid-revascularization-surveillance-project-100274311","NCT02850588","SVS VQI TransCarotid Revascularization Surveillance Project","TransCarotid Revascularization Surveillance Project of the Society for Vascular Surgery Vascular Quality Initiative","VQI-TCAR","Inclusion Criteria:\n\nAll patients undergoing TCAR or CEA both standard surgical risk and high surgical risk as defined by the CMS criteria published in the National Coverage Determination for Percutaneous Transluminal Angioplasty (20.7).\n\nExclusion Criteria:\n\n* Patients who have received a previous stent in the target artery.",{"count":95,"type":20},60000,"1 Year","The VQI TCAR Surveillance Project is designed to monitor the safety and effectiveness of stents placed directly into the carotid artery while reversing blood flow within the carotid artery to reduce stroke risk. It will compare this less-invasive surgical procedure with standard carotid endarterectomy in centers that participate in the Society for Vascular Surgery Vascular Quality Initiative.",[26],"2022-10-05",{"date":101,"type":42},"2022-10-07",{"date":103,"type":42},"2016-11-01",{"date":105,"type":20},"2027-12-31",{"name":107,"class":108},"Society for Vascular Surgery Patient Safety Organization","OTHER"]